SCHEMBL6928025

SCHEMBL6928025

CN(C)CCCOc1cccc(NC(=O)c2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.66
KDM1A O60341 1/20 0.66
TRPV1 Q8NER1 1/20 0.65
MCHR1 Q99705 3/20 0.61
CACNA1H O95180 2/20 0.60
CACNA1B Q00975 2/20 0.60
KDR P35968 1/20 0.58
ROCK2 O75116 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
ROCK1 Q13464 1/20 0.58
THRB P10828 1/20 0.57
MAPK1 P28482 1/20 0.56
MEN1 O00255 1/20 0.55
MAPT P10636 1/20 0.55
KMT2A Q03164 1/20 0.55
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920369 0.94 MCHR1 (0.68) MAOBKDM1ATRPV1MCHR1THRB
SCHEMBL6924167 0.87 MCHR1 (0.71) MCHR1CACNA1HCACNA1BKDRMEN1
SCHEMBL6925375 0.84 MCHR1 (0.78) MAOBKDM1ATRPV1MCHR1MAPK1
SCHEMBL6921976 0.81 MCHR1 (0.77) MCHR1CACNA1HCACNA1BKDRMAPT
SCHEMBL7225276 0.81 RXRA (0.67) ROCK2CYP3A4CYP2D6CYP2C9ROCK1
SCHEMBL6924993 0.80 CACNA1H (0.70) MCHR1CACNA1HCACNA1BKMT2AKDM4E
SCHEMBL4253111 0.79 TRPV1 (1.00) TRPV1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5182631 0.79 THRB (0.64) MAOBKDM1ATRPV1CYP3A4CYP2C9
SCHEMBL10679310 0.77 LSS (0.73) MAOBCACNA1BMAPTKMT2AKDM4E
SCHEMBL11877013 0.76 CACNA1B (0.60) MAOBKDM1ACACNA1HCACNA1BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 EP claimed
US-6515027-B1 Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 SMITHKLINE BEECHAM CORP. 2003-02-04 US claimed
JP-2002511879-A 2002-04-16 JP claimed
EP-1001766-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2001-04-04 EP claimed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP claimed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO claimed
EP-4143235-A1 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION IncellDx, Inc. (US) 2023-03-08 EP disclosed
WO-2021222069-A1 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION INCELLDX, INC. (US) 2021-11-04 WO disclosed
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 EP disclosed
US-6515027-B1 Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 SMITHKLINE BEECHAM CORP. 2003-02-04 US disclosed
EP-1001766-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2001-04-04 EP disclosed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP disclosed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO disclosed